The global biospecific antibody market size was estimated to be USD 578.4 million in 2023 and is expected to reach at USD 1,316.0 million by 2033 with a CAGR of 7.76% during the forecast period 2023-2033. Rising rates of chronic diseases including cancer, autoimmune conditions, and infectious diseases, increasing need for targeted medicines, and developments in antibody engineering technologies are some of the key drivers driving market expansion.
Increasing prevalence of chronic diseases is expected to fuel the market growth. For instance, according to research issued in 2022 by the National Association of Chronic Disease Directors, over 60% of adult Americans have at least one chronic disease. Furthermore, 90% of the $3.8 trillion in yearly healthcare spending in the country is attributed to persons with chronic illnesses and mental health conditions, according to the Centres for Disease Control and Prevention. Bispecific antibodies offer a promising path for personalized therapy and tailored therapies in various disease areas to treat such diseases.
By drug type, the catumaxoab was the highest revenue-grossing segment in the global biospecific antibody market in 2022 due to the monoclonal antibodies' limitations in drug resistance and treatment failure. A monoclonal biospecific trifunctional antibody called catumaxoab is used to treat malignant ascites in rats and mice. It was created by Trion Pharma and Fresenius Biotech. Catumaxoab, marketed as Removab, is given to patients with EpCAM-positive cancer after being licensed and undergoing clinical trials in the United States. The blinatumomab market is expected to expand throughout the forecast period. Specific types of acute lymphocytic leukaemia that have not responded to treatment with other medications or have come back in adults and children are treated with blinatumomab.
By indication, the cancer segment accounted the highest share in the global biospecific antibody market in 2022 owing to prevalence of chronic diseases such oncological disorders, autoimmune disorders, and infectious diseases. These treatments present a potential strategy since they concurrently target several disease processes. For the treatment of gastric cancer, more than 15 bispecific antibodies are currently being developed. Akeso Biopharma announced in March 2023 that enrolment in a phase III trial for Cadonilimab, which is used in conjunction with chemotherapy as first-line treatment for advanced stomach or gastroesophageal junction cancer, had reached its conclusion. The inflammatory & autoimmune disorder is expected to have fastest CAGR during the forecast period due to rising cases of autoimmune disorder.
By distribution channel, the hospital pharmacy was the highest revenue-generating segment in 2022 due to improved guidelines, supportive health reimbursement systems, and active government initiatives for chronic diseases. The retail pharmacy market is predicted to expand throughout the forecast period, mostly because of manufacturers' increased focus on growing distribution networks, substantial increase in cancer incidence, and improved health infrastructure.
In 2022, the North American region accounted for the highest revenue in the biospecific antibody market during the forecast period. This is attributed to existence of several market players and the various developments undertaken by them. Other factors driving the regional market include increasing R&D spending, technological developments, and rising demand for bispecific antibodies. Additionally, the increasing interest and confidence of businesses to spend in R&D has increased with the regulatory authorities' approval of a number of bispecific antibodies. For instance, the first bispecific B-cell maturation antigen, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), received FDA approval in October 2022. Europe is predicted to experience the fastest CAGR during the forecast period. With a focus on precision medicine and a supportive regulatory framework, the region is well-positioned to take advantage of the special advantages of bispecific antibodies. Collaborations and partnerships between regional and international stakeholders also aid in the expansion of the region.
Increasing prevalence of chronic diseases is expected to fuel the market growth. For instance, according to research issued in 2022 by the National Association of Chronic Disease Directors, over 60% of adult Americans have at least one chronic disease. Furthermore, 90% of the $3.8 trillion in yearly healthcare spending in the country is attributed to persons with chronic illnesses and mental health conditions, according to the Centres for Disease Control and Prevention. Bispecific antibodies offer a promising path for personalized therapy and tailored therapies in various disease areas to treat such diseases.
By drug type, the catumaxoab was the highest revenue-grossing segment in the global biospecific antibody market in 2022 due to the monoclonal antibodies' limitations in drug resistance and treatment failure. A monoclonal biospecific trifunctional antibody called catumaxoab is used to treat malignant ascites in rats and mice. It was created by Trion Pharma and Fresenius Biotech. Catumaxoab, marketed as Removab, is given to patients with EpCAM-positive cancer after being licensed and undergoing clinical trials in the United States. The blinatumomab market is expected to expand throughout the forecast period. Specific types of acute lymphocytic leukaemia that have not responded to treatment with other medications or have come back in adults and children are treated with blinatumomab.
By indication, the cancer segment accounted the highest share in the global biospecific antibody market in 2022 owing to prevalence of chronic diseases such oncological disorders, autoimmune disorders, and infectious diseases. These treatments present a potential strategy since they concurrently target several disease processes. For the treatment of gastric cancer, more than 15 bispecific antibodies are currently being developed. Akeso Biopharma announced in March 2023 that enrolment in a phase III trial for Cadonilimab, which is used in conjunction with chemotherapy as first-line treatment for advanced stomach or gastroesophageal junction cancer, had reached its conclusion. The inflammatory & autoimmune disorder is expected to have fastest CAGR during the forecast period due to rising cases of autoimmune disorder.
By distribution channel, the hospital pharmacy was the highest revenue-generating segment in 2022 due to improved guidelines, supportive health reimbursement systems, and active government initiatives for chronic diseases. The retail pharmacy market is predicted to expand throughout the forecast period, mostly because of manufacturers' increased focus on growing distribution networks, substantial increase in cancer incidence, and improved health infrastructure.
In 2022, the North American region accounted for the highest revenue in the biospecific antibody market during the forecast period. This is attributed to existence of several market players and the various developments undertaken by them. Other factors driving the regional market include increasing R&D spending, technological developments, and rising demand for bispecific antibodies. Additionally, the increasing interest and confidence of businesses to spend in R&D has increased with the regulatory authorities' approval of a number of bispecific antibodies. For instance, the first bispecific B-cell maturation antigen, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), received FDA approval in October 2022. Europe is predicted to experience the fastest CAGR during the forecast period. With a focus on precision medicine and a supportive regulatory framework, the region is well-positioned to take advantage of the special advantages of bispecific antibodies. Collaborations and partnerships between regional and international stakeholders also aid in the expansion of the region.
Segmentation: Biospecific Antibody Market Report 2022-2033
Biospecific Antibody Market Analysis & Forecast By Drug Type 2022-2033 (Revenue USD Mn)
- Catumaxoab
- Blinatumomab
- Duligotumab
Biospecific Antibody Market Analysis & Forecast By Indication 2022-2033 (Revenue USD Mn)
- Infectious
- Cancer
- CNS Disorders
- Inflammatory and Autoimmune Disorders
Biospecific Antibody Market Analysis & Forecast By Distribution Channel 2022-2033 (Revenue USD Mn)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Drug Stores
Biospecific Antibody Market Analysis & Forecast By Region 2022-2033 (Revenue USD Mn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Method
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biospecific Antibody Market: Drug Type Estimates & Trend Analysis
8. Biospecific Antibody Market: Indication Estimates & Trend Analysis
9. Biospecific Antibody Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Biospecific Antibody Market
12. Europe Global Biospecific Antibody Market
13. Asia Pacific Global Biospecific Antibody Market
14. Latin America Global Biospecific Antibody Market
15. MEA Global Biospecific Antibody Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Amgen
- Genentech
- Janssen
- Immunocore
- Taisho Pharmaceutical
- Bayer AG
- Pfizer Inc.
- Merck Amgen
- OncoMed Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 578.4 million |
| Forecasted Market Value ( USD | $ 1316 million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
